Cancer Steering Committee

The Biomarkers Consortium’s Cancer, Inflammation and Immunity, Metabolic Disorders and Neuroscience Steering Committees are responsible for identifying and moving forward promising pre-competitive biomarkers projects for implementation by the Biomarkers Consortium, as well as overseeing each individual project under its purview. The members of each Steering Committee represent a variety of sectors, including academia, government, industry and not-for-profit/advocacy organizations, and are led by two co-chairs representing two of the following three sectors: academia, government or industry.

Gary Kelloff, M.D., NIH/NCI, (Co-Chair)

Emmett Schmidt, M.D., Ph.D., Merck (Co-Chair)

Alexandre Akoulitchev, Ph.D., Oxford Biodynamics

Jeff Allen, Ph.D., Friends of Cancer Research

Daniel Auclair, Ph.D., AstraZeneca

J. Carl Barrett, Ph.D., University of North Carolina

Christopher Below, Ph.D., Biognosys

Michelle Berny-Lang, Ph.D., NCI

Donald A. Berry, Ph.D., MD Anderson Cancer Center

Vikram Bhadrasain, M.D., NCI

Jonathan Blackburn, Ph.D., Sengenics

Gary Borzillo, Ph.D., Janssen

Anita Boyapati, Ph.D., Regeneron

Trixia Camacho, PharmD, BMS

Claudio Carini, Ph.D., Kings College London

Hearn Jay Cho, M.D., Ph.D., The Multiple Myeloma Research Foundation

Caroline Chung, M.D., MD Anderson (QIBA-RSNA)

Steven Cole, NCI

Cecile Combeau, Ph.D., Sanofi

Catherine Conway, Danaher

Adam Corner, BioRad

Michelle Douglas, Ph.D., Genentech

Jeff Ecsedy, Ph.D., Ikena Oncology

Michael Espey, Ph.D., NCI

Sharon Friedlander, Ph.D., Takeda Pharmaceuticals International, Inc.

Steven Gendreau, Ph.D., Genentech

Ed Driggers, Ph.D., General Metabolics

Ida Grundberg, Ph.D., Olink

Stanley R. Hamilton, M.D., City of Hope National Medical Center

Sean Hanlon, Ph.D., NCI

Lyndsay Harris, M.D., NCI

Stephanie Hennek, Ph.D., PathAI

Brandon Higgs, Ph.D., Genmab US, Inc.

James Hnatyszyn, Ph.D., Seattle Genetics, Inc.

Steffan Ho, M.D., Ph.D., Pfizer

Rob Iannone, M.D., Jazz Pharmaceuticals

Peter Intile, SITC

Taylor Jensen, Ph.D., LabCorp

John Jessup, M.D., Institute for Bioscience and Biotechnology Research

Sarah Kehoe, Ph.D., Danaher

Jayaprakash Karkera, Ph.D., GlaxoSmithKline

Morten Karsdal, Ph.D., Nordic Bioscience

Ilan (Lanny) Kirsch, M.D., Adaptive Biotechnologies

Kate Lyden, Ph.D., VivoSense

Derek McCartney, M.S., Biognosys

Robert McCormack, Ph.D.

Doug Mirsky, Ph.D., Digital Medicine Society

Helen Moore, Ph.D., NIH/NCI

Larry Nagahara, Ph.D., John’s Hopkins University

Michael O’Neal, M.D., Clario

Mariaelena Occhipinti, Ph.D., Radiomics

Geoff Oxnard, M.D., Eli Lily & Company

Ketan Patel, Ph.D., Clarivate

Snehal Patel, Ph.D., Association for Molecular Pathology

Reena Philip, Ph.D., FDA/OCE

Jelena Põlajeva, Ph.D., Clarivate

Vladimir Popov, Ph.D., FNLCR/NCI

Scott Knowles Pruitt, M.D., Ph.D.,Merck

Elizabeth Punnoose, Ph.D., Genentech

Anita Reddy, Ph.D., Amgen

Henry Rodriguez, Ph.D., NIH/NCI

Vanessa Rodrik-Outmezguine, Ph.D., Eli Lilly & Company

Marijana Rucevic, Ph.D., Olink Proteomics

Simon Saraga, M.S., Danaher

Amy Kate Sasser, Ph.D., Genmab US, Inc.

Lawrence Schwartz, M.D., Memorial Sloan Kettering

Maggie Scully, Ph.D.,Frederick Natl. Lab. For Cancer Research

Christine Serway, Ph.D., Danaher

Alex Snyder, Ph.D., Generate Biomedicines (SITC)

Howard Spiegel, Olink Proteomic

Magadelena Thurin, Ph.D., NIH/NCI

Peter Ujhazy, M.D., Ph.D., NIH/NCI

Tamar Uziel, Ph.D., AbbVie

Sarah Valentine, Digital Medicine Society

Megann Vaughn, M.B.A., LabCorp

Wim Vos. Ph.D., Radiomics

Sean Walsh, Ph.D., Radiomics

Tony Wagner, Ph.D., Jazz Pharmaceuticals

Mike Ward, Ph.D., Alector

Mickey Williams, Ph.D., NIH/NCI

Joel Wommack, Ph.D., SomaLogic

Rebekah Zinn, Ph.D., FDA